Investigating how specific calcium signaling affects heart muscle growth
Official title: Perinuclear Ryanodine Receptors and Cardiac Remodeling
Funded at University of Connecticut Sch of Med/dnt · NIH-10847458 · Data updated 2026-11-12
This study is looking at how calcium signals in heart cells affect heart muscle growth, especially in people with heart disease, to find new ways to treat or prevent these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $558,716 |
| NIH project number | 5R01HL166547-02 |
| Project ID | NIH-10847458 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions that lead to pathological cardiac hypertrophy, such as heart failure or other cardiac disorders.
✕Less likely to help
Patients with non-cardiac related conditions or those without any signs of cardiac hypertrophy may not benefit from this research.
What this research studies
This research focuses on understanding the role of calcium signaling in the development of heart muscle growth, particularly in conditions that lead to heart disease. The researchers aim to identify specific calcium microdomains that regulate gene transcription in heart cells, which could lead to targeted therapies. By studying the interactions between calcium channels and signaling proteins, they hope to uncover new mechanisms that contribute to pathological heart growth. This could ultimately help in developing treatments that prevent or reverse heart disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target heart muscle growth, improving outcomes for patients with heart disease.
How similar studies have gone: Previous research has shown promise in targeting calcium signaling pathways for heart disease treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
-
University of Connecticut Sch of Med/dnt
Farmington, United States Active
Researchers
- Principal investigator: Dodge-Kafka, Kimberly L — University of Connecticut Sch of Med/dnt
- Study coordinator: Dodge-Kafka, Kimberly L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.